Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01301963 · ClinicalTrials.gov registry record · Phase 3
Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide
A Phase 3 study, sponsored by Case Comprehensive Cancer Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 9
- Enrollment target
NCT01301963: Clinical Trial Phase 3 study, sponsored by Case Comprehensive Cancer Center.
NCT01301963 is a Phase 3 study that was terminated before completion, run by Case Comprehensive Cancer Center. The registered enrollment target is 9 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01301963, a Phase 3 study, was terminated before completion, sponsored by Case Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 9 participants
- Enrollment target
Study Summary
This clinical trial studies filgrastim (G-CSF) with or without plerixafor in treating patients with multiple myeloma (MM) previously treated with lenalidomide. Giving colony-stimulating factors, such as G-CSF, and plerixafor helps stem cells move from the patient's bone marrow to the blood so they can be collected and stored
Interventions
- BIOLOGICAL filgrastim
- DRUG plerixafor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2011-07 |
| Phase | Phase 3 |
Why NCT01301963 stopped before completion
NCT01301963 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which filgrastim is the first listed.
NCT01301963 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01301963 about?
NCT01301963 is a clinical study titled "Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide". This clinical trial studies filgrastim (G-CSF) with or without plerixafor in treating patients with multiple myeloma (MM) previously treated with lenalidomide. Giving colony-stimulating factors, such as G-CSF, and plerixafor helps stem cells move from the patient's bone marrow to the blood so they c...
What is the current status of trial NCT01301963?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 9 participants. The study started on 2011-07.
What interventions are being tested in trial NCT01301963?
The interventions under investigation include: filgrastim (BIOLOGICAL), plerixafor (DRUG).
Who is sponsoring clinical trial NCT01301963?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01301963's enrollment target sits among peer trials
9 1992nd of 2000 higher than 8 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia